PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: PIPELINE PART 07: MARKET SEGMENTATION BY PRODUCT Market segmentation by product Comparison by product OCALIVA - Market size and forecast 2018-2023 Ursodiol - Market size and forecast 2018-2023 Others - Market size and forecast 2018-2023 Market opportunity by product PART 08: CUSTOMER LANDSCAPE PART 09: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES Market drivers Market challenges PART 12: MARKET TRENDS Strong pipeline Increasing drug designations Advent of regenerative therapy PART 13: VENDOR LANDSCAPE Overview Landscape disruption Competitive scenario PART 14: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors Abbott Laboratories Allergan Plc Eli Lilly and Co. Intercept Pharmaceuticals Inc. Takeda Pharmaceutical Co. Ltd. PART 15: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 16: EXPLORE TECHNAVIO Exhibit 01: Global pharmaceuticals market Exhibit 02: Segments of global pharmaceuticals market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 06: Market size 2018 Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 08: Global market: Year-over-year growth 2019-2023 (%) Exhibit 09: Five forces analysis 2018 Exhibit 10: Five forces analysis 2023 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2018 Exhibit 17: Global primary biliary cholangitis therapeutics market pipeline: Overview Exhibit 18: Global primary biliary cholangitis therapeutics market pipeline: Snapshot Exhibit 19: Product - Market share 2018-2023 (%) Exhibit 20: Comparison by product Exhibit 21: OCALIVA - Market size and forecast 2018-2023 ($ millions) Exhibit 22: OCALIVA - Year-over-year growth 2019-2023 (%) Exhibit 23: Ursodiol - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Ursodiol - Year-over-year growth 2019-2023 (%) Exhibit 25: Others - Market size and forecast 2018-2023 ($ millions) Exhibit 26: Others - Year-over-year growth 2019-2023 (%) Exhibit 27: Market opportunity by product Exhibit 28: Customer landscape Exhibit 29: Market share by geography 2018-2023 (%) Exhibit 30: Geographic comparison Exhibit 31: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 32: North America - Year-over-year growth 2019-2023 (%) Exhibit 33: Top 3 countries in North America Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 35: Europe - Year-over-year growth 2019-2023 (%) Exhibit 36: Top 3 countries in Europe Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 38: Asia - Year-over-year growth 2019-2023 (%) Exhibit 39: Top 3 countries in Asia Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 41: ROW - Year-over-year growth 2019-2023 (%) Exhibit 42: Top 3 countries in ROW Exhibit 43: Key leading countries Exhibit 44: Market opportunity Exhibit 45: Impact of drivers and challenges Exhibit 46: Vendor landscape Exhibit 47: Landscape disruption Exhibit 48: Vendors covered Exhibit 49: Vendor classification Exhibit 50: Market positioning of vendors Exhibit 51: Abbott Laboratories - Vendor overview Exhibit 52: Abbott Laboratories - Business segments Exhibit 53: Abbott Laboratories - Organizational developments Exhibit 54: Abbott Laboratories - Geographic focus Exhibit 55: Abbott Laboratories - Segment focus Exhibit 56: Abbott Laboratories - Key offerings Exhibit 57: Abbott Laboratories - Key customers Exhibit 58: Allergan Plc - Vendor overview Exhibit 59: Allergan Plc - Business segments Exhibit 60: Allergan Plc - Organizational developments Exhibit 61: Allergan Plc - Geographic focus Exhibit 62: Allergan Plc - Segment focus Exhibit 63: Allergan Plc - Key offerings Exhibit 64: Allergan Plc - Key customers Exhibit 65: Eli Lilly and Co. - Vendor overview Exhibit 66: Eli Lilly and Co. - Business segments Exhibit 67: Eli Lilly and Co. - Organizational developments Exhibit 68: Eli Lilly and Co. - Geographic focus Exhibit 69: Eli Lilly and Co. - Segment focus Exhibit 70: Eli Lilly and Co. - Key offerings Exhibit 71: Eli Lilly and Co. - Key customers Exhibit 72: Intercept Pharmaceuticals Inc. - Vendor overview Exhibit 73: Intercept Pharmaceuticals Inc. - Business segments Exhibit 74: Intercept Pharmaceuticals Inc. - Organizational developments Exhibit 75: Intercept Pharmaceuticals Inc. - Geographic focus Exhibit 76: Intercept Pharmaceuticals Inc. - Key offerings Exhibit 77: Intercept Pharmaceuticals Inc. - Key customers Exhibit 78: Takeda Pharmaceutical Co. Ltd. - Vendor overview Exhibit 79: Takeda Pharmaceutical Co. Ltd. - Business segments Exhibit 80: Takeda Pharmaceutical Co. Ltd. - Organizational developments Exhibit 81: Takeda Pharmaceutical Co. Ltd. - Geographic focus Exhibit 82: Takeda Pharmaceutical Co. Ltd. - Key offerings Exhibit 83: Takeda Pharmaceutical Co. Ltd. - Key customers Exhibit 84: Validation techniques employed for market sizing Exhibit 85: Definition of market positioning of vendors

Abbott Laboratories Allergan Plc Eli Lilly and Co. Intercept Pharmaceuticals Inc. Takeda Pharmaceutical Co. Ltd.